Using reverse transcription-PCR and immunohistochemical staining of matched tumor and nontumor samples, Sutterluty et al. reported in 2007 that Spry2 expression, but not that of Spry1, is consistently reduced at mRNA and protein levels in non-small cell lung cancer (NSCLC) tissues [52]. The gene discussed is SPRY1; the disease is neoplasm.